Avanos Medical, Inc.

DB:8HH Stock Report

Market Cap: €766.3m

Avanos Medical Valuation

Is 8HH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8HH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8HH (€18.4) is trading above our estimate of fair value (€6.35)

Significantly Below Fair Value: 8HH is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8HH?

Key metric: As 8HH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 8HH. This is calculated by dividing 8HH's market cap by their current earnings.
What is 8HH's PE Ratio?
PE Ratio37x
EarningsUS$21.70m
Market CapUS$802.80m

Price to Earnings Ratio vs Peers

How does 8HH's PE Ratio compare to its peers?

The above table shows the PE ratio for 8HH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.5x
PHH2 Paul Hartmann
12.5xn/a€742.3m
DRW3 Drägerwerk KGaA
7.2x2.0%€798.0m
EUZ Eckert & Ziegler
24.5x5.9%€879.3m
SBS Stratec
33.6x25.4%€336.7m
8HH Avanos Medical
37xn/a€802.8m

Price-To-Earnings vs Peers: 8HH is expensive based on its Price-To-Earnings Ratio (37x) compared to the peer average (19.5x).

Price to Earnings Ratio vs Industry

How does 8HH's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
8HH 37.0xIndustry Avg. 29.7xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 8HH is expensive based on its Price-To-Earnings Ratio (37x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is 8HH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8HH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8HH's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8HH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.40
€20.69
+12.4%
11.1%€22.99€18.39n/a2
Nov ’25€17.10
€20.69
+21.0%
11.1%€22.99€18.39n/a2
Oct ’25€21.40
€23.01
+7.5%
5.9%€24.36€21.66n/a2
Sep ’25€21.80
€23.55
+8.0%
5.9%€24.93€22.16n/a2
Aug ’25€22.00
€23.55
+7.0%
5.9%€24.93€22.16n/a2
Jul ’25€18.30
€21.91
+19.7%
14.9%€25.17€18.64n/a2
Jun ’25€18.30
€21.91
+19.7%
14.9%€25.17€18.64n/a2
May ’25€17.40
€21.74
+24.9%
14.9%€24.98€18.50n/a2
Apr ’25€18.30
€21.74
+18.8%
14.9%€24.98€18.50n/a2
Mar ’25€17.00
€21.74
+27.9%
14.9%€24.98€18.50n/a2
Feb ’25€17.60
€21.68
+23.2%
14.9%€24.91€18.45n/a2
Jan ’25€20.20
€25.08
+24.1%
17.0%€29.34€20.82n/a2
Dec ’24€19.50
€25.08
+28.6%
17.0%€29.34€20.82n/a2
Nov ’24€17.10
€25.08
+46.6%
17.0%€29.34€20.82€17.102
Oct ’24€19.20
€25.51
+32.9%
10.7%€28.24€22.78€21.402
Sep ’24€19.30
€25.51
+32.2%
10.7%€28.24€22.78€21.802
Aug ’24€21.60
€25.33
+17.3%
10.7%€28.05€22.62€22.002
Jul ’24€23.20
€27.31
+17.7%
12.5%€30.95€22.76€18.303
Jun ’24€22.20
€27.97
+26.0%
12.5%€31.69€23.31€18.303
May ’24€26.60
€27.35
+2.8%
12.9%€32.07€23.58€17.403
Apr ’24€26.20
€27.35
+4.4%
12.9%€32.07€23.58€18.303
Mar ’24€26.20
€27.35
+4.4%
12.9%€32.07€23.58€17.003
Feb ’24€28.00
€26.62
-4.9%
14.2%€31.94€23.49€17.603
Jan ’24€25.20
€28.37
+12.6%
16.3%€34.86€24.61€20.203
Dec ’23€25.40
€28.37
+11.7%
16.3%€34.86€24.61€19.503
Nov ’23€22.00
€31.93
+45.1%
18.4%€39.14€24.72€17.103

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%